Pharmaceutical News

RSS

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

New challenges to FDA's 'no risk' classification of mercury fillings

FDA Device Division, still concerned about mercury toxicity in American dentistry, is convening yet another professional panel review regarding safety issues. A nationwide convergence of scientists, dental and medical professionals, lead by the International Academy of Oral Medicine and Toxicology (IAOMT) are provoking new challenges to the Food and Drug Administration's (FDA) July'09 "no risk" classification of mercury fillings .

10 Dec 2010

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

Pfizer Inc. announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

10 Dec 2010

FDA approves Mylan's generic Adalat CC Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Bayer's Adalat® CC Tablets, a treatment for hypertension.

10 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications filed by Pisgah Labs with the United States Patent and Trademark Office (http://www.uspto.gov).

10 Dec 2010

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus AS today announced that it has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).

10 Dec 2010

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

10 Dec 2010

McNeil recalls ROLAIDS Ultra Strength SoftChews and SoftChews plus Gas Relief in Canada

McNeil Consumer Healthcare, Division of Johnson & Johnson Inc. is voluntarily recalling all lots of ROLAIDS® Ultra Strength SoftChews® and ROLAIDS® Ultra Strength SoftChews® plus Gas Relief distributed in Canada.

10 Dec 2010

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.

10 Dec 2010

News outlets report on polio outbreaks in Central, East Africa

"Bad immunisation strategy has been blamed for an outbreak of polio, which has killed nearly 200 and is believed to have caused paralysis in more than 2,000 others across Angola, Congo and the Democratic Republic of the Congo," the Mail & Guardian writes in a story examining the emergence of the disease in the three countries and efforts to control it.

10 Dec 2010

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey.

10 Dec 2010

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

9 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

OpEds: How debt panel 'punted' on health costs; Sustainable 'doc fix;' Arizona 'death panel;' Sebelius on flu vaccine

In this Kaiser Health News column, Austin Frakt and Aaron Carroll write: "By some accounts, the Republican takeover of the House is a game changer for health reform. Already, it has reinvigorated debate over the law, and the media have focused on what federal legislators can or will do to alter it. But more attention should be directed elsewhere. The future trajectory of health reform will be shaped far more by interest group agendas and state-level actions than by the new House leadership's stated plans. Not only has the game changed, but so have the most important players" (12/9).

9 Dec 2010

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Hemispherx Biopharma, Inc. announced that the Company has amended its June 15, 2010 agreement with GP Pharm Latinoamerica ("GP Pharm"), an affiliate company of Spanish GP Pharm SA (www.gp-pharm.com) to immediately include Mexico in the Territory under the Sales, Marketing, Distribution and Supply Agreement.

9 Dec 2010

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Techulon Inc., an early stage life sciences company has signed an agreement with Nacalai USA, Inc. and its parent company Nacalai Tesque, Inc. for distribution of its Glycofect Transfection Reagent platform products in Japan. Glycofect is a polymeric transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used by government, university and corporate laboratories around the world for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

9 Dec 2010

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week's HIV DART 2010 conference, "Frontiers in Drug Development for Antiretroviral Therapies," in Los Cabos, Mexico. The conference brings international researchers together to discuss the latest developments in the fight against HIV/AIDS.

9 Dec 2010

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amgen/Pfizer's Enbrel is the leading tumor necrosis factor -alpha inhibitor prescribed in newly diagnosed rheumatoid arthritis patients, outpacing Abbott's Humira in the first three lines of treatment.

9 Dec 2010

Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

Medisafe 1 Technologies Corp., a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company conducted an official demonstration of its barcoded syringe locking device at Israel's National Ministry of Health.

9 Dec 2010

Pharmaceutical News

Depression drug appears effective in reducing pain associated with breast cancer treatment

New challenges to FDA's 'no risk' classification of mercury fillings

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

FDA approves Mylan's generic Adalat CC Tablets ANDA

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

McNeil recalls ROLAIDS Ultra Strength SoftChews and SoftChews plus Gas Relief in Canada

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

News outlets report on polio outbreaks in Central, East Africa

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

OpEds: How debt panel 'punted' on health costs; Sustainable 'doc fix;' Arizona 'death panel;' Sebelius on flu vaccine

Hemispherx amends Ampligen agreement with GP Pharm to include Mexico

Nacalai to distribute Techulon's Glycofect Transfection Reagent platform products in Japan

Genetic Immunity to present DermaVir and DermaPrep transdermal delivery system at HIV DART 2010 conference

Enbrel outperforms Humira in treating newly diagnosed RA patients: Report

Medisafe 1 Technologies demonstrates syringe locking device at Israel's National Ministry of Health

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News